

## Recommendations for VoYCCG from York and Scarborough Medicines Commissioning Committee June 2016

	Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential cost impact
1	Adapalene 0.1% / Benzoyl peroxide 2.5%) Gel "Epiduo"	Mild acne	Approved (omission from March 16 MCC recommendation)	2 <sup>nd</sup> line topical therapy when combination of benzyl peroxide and retinoid is required as combination therapy can have an additive effect and improve patients' compliance. Patients starting on oral anti-inflammatory antibiotics for acne. In combination with an oral antibiotic to treat multiple pathogenic factors of acne, reduce the population of P acnes and prevent antibiotic resistance.	2 <sup>nd</sup> line	Green	
2	Sacubitril/Valsartan (Entresto)	Treatment of symptomatic chronic heart failure with reduced ejection fraction	Approved as per NICE guidance (confirmation of RAG status from May MCC recommendation)	NICE approved	As an option for treating symptomatic chronic heart failure with reduced ejection fraction as per NICE	Amber – Specialist initiation	£0.5M to £1M dependent on estimates – no definitive cost predictions currently available

3	Canagliflozin, dapagliflozin and empagliflozin	<a href="#">TA390</a> : as monotherapies for treating type 2 diabetes	Approved as per NICE guidance	NICE approved	As an option as monotherapies for treating type 2 diabetes as per NICE guidance TA390	Green	No significant cost – similar price to current treatments
4	Cabazitaxel	<a href="#">TA 391</a> : for hormone-relapsed metastatic prostate cancer treated with docetaxel	Approved as per NICE guidance	NICE approved; for funding by NHSE	As per NICE TA391	Red	No cost to CCGs - funded by NHSE
5	Sodium hyaluronate 0.2% HYLO-FORTE	Preservative free option for significant dry eye	Approved	Cost effective preparation	Amendment to May 16 MCC approved Prescribing Guidance for Dry Eye and Corneal Damage/Erosion/Dystr ophy position	Amber - Specialist recommendation	Product approved as being the most appropriate cost effective treatment
6	Sodium hyaluronate 0.4% CLINITAS	Preservative free option for significant dry eye	Approved	Cost effective preparation	Amendment to May 16 MCC approved Prescribing Guidance for Dry Eye and Corneal Damage/Erosion/Dystr ophy position	Amber - Specialist recommendation	Product approved as being the most appropriate cost effective treatment
7	Carmellose 0.5%, glycerol 1% & castor oil 0.25% OPTIVE PLUS	Evaporative Dry Eye	Approved	Cost effective preparation	Amendment to May 16 MCC approved Prescribing Guidance for Dry Eye and Corneal Damage/Erosion/Dystr	Amber - Specialist recommendation	Product approved as being the most appropriate cost effective treatment

					ophy position		
8	Propylene glycol, hydroxypropyl guar, mineral oil, etc. SYSTANE BALANCE	Evaporative Dry Eye	Approved	Cost effective preparation	Amendment to May 16 MCC approved Prescribing Guidance for Dry Eye and Corneal Damage/Erosion/Dystr ophy position	Amber - Specialist recommendation	Product approved as being the most appropriate cost effective treatment
9	Acetylcysteine 5% ILUBE	Filamentary keratitis	Approved	Cost effective preparation	Amendment to May 16 MCC approved Prescribing Guidance for Dry Eye and Corneal Damage/Erosion/Dystr ophy position	Amber - Specialist recommendation	Product approved as being the most appropriate cost effective treatment
10	Sodium chloride 5% with sodium hyaluronate 0.15% ODM5	Corneal oedema / Fuchs endothelial dystrophy	Approved	Cost effective preparation	Amendment to May 16 MCC approved Prescribing Guidance for Dry Eye and Corneal Damage/Erosion/Dystr ophy position	Amber - Specialist recommendation	Product approved as being the most appropriate cost effective treatment
11	Oral doxycycline	Posterior blepharitis	Approved	Preferred antibiotic when oral antibiotic treatment required	Addition to May 16 MCC approved Prescribing Guidance for Dry Eye and Corneal	Green	Product approved as being the most appropriate cost effective treatment

					Damage/Erosion/Dystr ophy		
12	Oral azithromycin	Posterior blepharitis	Approved	Preferred antibiotic when oral antibiotic treatment required	Addition to May 16 MCC approved Prescribing Guidance for Dry Eye and Corneal Damage/Erosion/Dystr ophy	Green	Product approved as being the most appropriate cost effective treatment